Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Genmab and Janssen Team Up to Develop Next-Generation CD38 Antibody

Denmark-based Genmab A/S and Janssen Biotech will collaborate on a successor to the multiple myeloma drug Darzalex with the development of a next-generation CD38 antibody product for the treatment of multiple myeloma and diffuse large B-cell lymphoma.

Read More »

Forty Seven Inc. and Acerta Enter Collaboration

Clinical-stage immuno-oncology company Forty Seven Inc. announced a collaboration with Acerta Pharma, AstraZeneca’s hematology research and development center of excellence.

Read More »

Rare manufacturing glitch raises concern over CAR-T therapies: study

A single leukemia cell inadvertently got mixed in with a batch of a patient’s immune cells that were being manufactured into a CAR-T cell therapy and it acquired resistance to the treatment with deadly results, University of Pennsylvania researchers reported.

Read More »

Novartis strikes deal with Chinese firm to make Kymriah

Chinese manufacturer Cellular Biomedicine has been enlisted to make Novartis’ $475,000 gene-modifying cancer treatment Kymriah as the Swiss drugmaker intends to win approval for the therapy in the world’s most populous country.

Read More »

Novartis wins EU approval for blood cancer therapy Kymriah

Novartis received European approval for Kymriah, the Swiss drugmaker’s gene-modifying therapy for blood cancer.

Read More »

Novartis Halts Planned Price Increases For Drugs Amid Scrutiny of Relationship With Trump Attorney

Novartis is halting planned price increases on the Swiss pharma giant’s medications after President Donald Trump took Pfizer to task over price hikes, with Pfizer subsequently agreeing to roll back the company’s price increases.

Read More »

Kymriah wins speedy reviews in U.S., Europe

Novartis was granted fast-track reviews of its cell therapy Kymriah for blood cancers in the United States and Europe.

Read More »

Novartis seeks EU approval for cell therapy Kymriah

Novartis submitted its cell therapy Kymriah for European approval in two forms of blood cancer, seeking to expand the use of the new treatment.

Read More »

FDA approves Gilead cancer gene therapy

U.S. regulators approved a new therapy for a type of lymphoma, which was developed by Gilead Sciences Inc.’s Kite Pharma.

Read More »

Kite Announces Landmark Study of Refractory Aggressive Non-Hodgkin Lymphoma (SCHOLAR-1) Outcomes Published in the Journal BLOOD

Kite Pharma Inc. highlighted the publication of the first large-scale multi-institutional analysis of outcomes of patients with refractory aggressive non-Hodgkin lymphoma (NHL) in the latest electronic edition of BLOOD.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom